title: New perspectives with interferon alpha. The German CML study group experience.
authors.affiliation: III. Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Hehlmann
authors.forename: H
authors.initials: H
authors.lastname: Ansari
authors.forename: V
authors.initials: V
authors.lastname: Adelberger
authors.forename: B
authors.initials: B
authors.lastname: Heinze
authors.forename: K
authors.initials: K
authors.lastname: Hossfeld
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
mesh_terms: D002066:Busulfan / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea